Plaza VII, Suite 3300
45 South Seventh Street
Minneapolis, MN 55402-1609
www.Oppenheimer.com
|
Direct: |
(612) 607-7287 |
|
Main: |
(612) 607-7000 |
|
Fax: |
(612) 607-7100 |
|
E-Mail: |
ACulbert@oppenheimer.com |
May 21, 2010
VIA EDGAR AND FACSIMILE
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
|
Attn: |
Mr. Jeffrey Riedler |
|
|
Assistant Director |
|
|
Mail Stop 4720 |
|
|
|
|
Re: |
BioSante Pharmaceuticals, Inc. |
|
|
Post-Effective Amendment No. 1 to Registration Statement on Form S-3 |
|
|
File Number: 333-156276 |
|
|
Filed May 14, 2010 |
Dear Mr. Riedler:
We are responding on behalf of BioSante Pharmaceuticals, Inc., a Delaware corporation, to your letter, dated May 19, 2010, to Mr. Phillip B. Donenberg, Chief Financial Officer, Treasurer and Secretary of BioSante, regarding BioSante’s Post-Effective Amendment No. 1 to Registration Statement on Form S-3 (File No. 333-156276).
For your convenience, please note that your comment is repeated below in italicized type, and BioSante’s response is provided below such comment.
Incorporation of Certain Documents by Reference, page 20
1. Comment: Please amend your registration statement to incorporate your current report on Form 8-K filed on March 5, 2010 by reference.
Response: In response to the Staff’s comment, BioSante amended the registration statement to incorporate by reference BioSante’s current report on Form 8-K as filed with the Commission on March 5, 2010.
* * * * *
In connection with this response, BioSante Pharmaceuticals, Inc. acknowledges that:
1. BioSante is responsible for the adequacy and accuracy of the disclosure in the filing;
2. Staff comments or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing; and
3. BioSante may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
After you have had an opportunity to review the above response to your comment, please call me at (612) 607-7287 to discuss any further questions or comments you might have concerning BioSante’s responses.
Very truly yours,
|
/s/ Amy E. Culbert |
|
Amy E. Culbert
cc: Stephen M. Simes, BioSante Pharmaceuticals, Inc.
Phillip B. Donenberg, BioSante Pharmaceuticals, Inc.